Stephane Thibodeau , Paul Nguyen , Andrew Robinson , Fabio Ynoe de Moraes , Jason Pantarotto , Timothy P. Hanna
{"title":"与 III 期非小细胞肺癌患者接受治疗和治疗意向相关的医疗保健系统因素:安大略省基于人口的研究","authors":"Stephane Thibodeau , Paul Nguyen , Andrew Robinson , Fabio Ynoe de Moraes , Jason Pantarotto , Timothy P. Hanna","doi":"10.1016/j.ctro.2024.100873","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease, with a spectrum of anatomic extent, health status, and treatment approaches. Receipt of treatment and its intent should be independent of health system factors where care quality is optimal. We investigated the degree that modifiable health system factors are associated with receipt of treatment and treatment intent in stage III NSCLC in a large, universal health system.</div></div><div><h3>Methods</h3><div>This was a population-based, retrospective cohort study with health administrative data from Ontario, Canada, 2010–2018 for those aged ≥ 20 years, with AJCC 7 or 8 stage III NSCLC. We explored health system factors associated with NSCLC treatment: region of residence, diagnostic interval, travel distance, advanced radiation (e.g. IMRT, VMAT) and systemic therapy treatment volumes, and year of treatment (treatment era). The relative risk (RR) of (1) any treatment versus no treatment, and (2) palliative versus non-palliative treatment was determined, using multivariable stepwise Poisson regression models. We adjusted for patient, disease, and treatment factors.</div></div><div><h3>Results</h3><div>We identified 7,093 people with stage III NSCLC between 2010 and 2018. There were no health system factors associated with receipt of treatment versus no treatment in adjusted analysis. The major health system factor associated with palliative intent was region of residence (RR: Region ranges from 0.88 to 1.67, p < 0.001). Stratifying by era (2010–2012 vs. 2013–2015 vs. 2016–2018), there was an increase in receipt of curative treatment and use of advanced radiotherapy techniques and immunotherapy over time, but regional variation of treatment intent was similar.</div></div><div><h3>Conclusions</h3><div>Region of residence emerged as the major health system factor associated with treatment intent for stage III NSCLC. This variation remained, even as advances in radiotherapy and systemic therapy were adopted. Our study suggests possible opportunities to improve care outcomes by addressing unexplained regional variation in care.</div></div>","PeriodicalId":10342,"journal":{"name":"Clinical and Translational Radiation Oncology","volume":"50 ","pages":"Article 100873"},"PeriodicalIF":2.7000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Health care system factors associated with receipt of treatment and treatment intent in stage III non-small cell lung cancer: A population-based study in Ontario\",\"authors\":\"Stephane Thibodeau , Paul Nguyen , Andrew Robinson , Fabio Ynoe de Moraes , Jason Pantarotto , Timothy P. Hanna\",\"doi\":\"10.1016/j.ctro.2024.100873\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease, with a spectrum of anatomic extent, health status, and treatment approaches. Receipt of treatment and its intent should be independent of health system factors where care quality is optimal. We investigated the degree that modifiable health system factors are associated with receipt of treatment and treatment intent in stage III NSCLC in a large, universal health system.</div></div><div><h3>Methods</h3><div>This was a population-based, retrospective cohort study with health administrative data from Ontario, Canada, 2010–2018 for those aged ≥ 20 years, with AJCC 7 or 8 stage III NSCLC. We explored health system factors associated with NSCLC treatment: region of residence, diagnostic interval, travel distance, advanced radiation (e.g. IMRT, VMAT) and systemic therapy treatment volumes, and year of treatment (treatment era). The relative risk (RR) of (1) any treatment versus no treatment, and (2) palliative versus non-palliative treatment was determined, using multivariable stepwise Poisson regression models. We adjusted for patient, disease, and treatment factors.</div></div><div><h3>Results</h3><div>We identified 7,093 people with stage III NSCLC between 2010 and 2018. There were no health system factors associated with receipt of treatment versus no treatment in adjusted analysis. The major health system factor associated with palliative intent was region of residence (RR: Region ranges from 0.88 to 1.67, p < 0.001). Stratifying by era (2010–2012 vs. 2013–2015 vs. 2016–2018), there was an increase in receipt of curative treatment and use of advanced radiotherapy techniques and immunotherapy over time, but regional variation of treatment intent was similar.</div></div><div><h3>Conclusions</h3><div>Region of residence emerged as the major health system factor associated with treatment intent for stage III NSCLC. This variation remained, even as advances in radiotherapy and systemic therapy were adopted. Our study suggests possible opportunities to improve care outcomes by addressing unexplained regional variation in care.</div></div>\",\"PeriodicalId\":10342,\"journal\":{\"name\":\"Clinical and Translational Radiation Oncology\",\"volume\":\"50 \",\"pages\":\"Article 100873\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Translational Radiation Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405630824001502\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405630824001502","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的 III 期非小细胞肺癌(NSCLC)是一种异质性疾病,其解剖范围、健康状况和治疗方法各不相同。在医疗质量达到最佳的情况下,接受治疗及其意向应不受医疗系统因素的影响。方法这是一项基于人群的回顾性队列研究,使用的是加拿大安大略省 2010-2018 年的卫生管理数据,研究对象为年龄≥ 20 岁、AJCC 7 期或 8 期 III 期 NSCLC 患者。我们探讨了与 NSCLC 治疗相关的卫生系统因素:居住地区、诊断间隔、旅行距离、晚期放射治疗(如 IMRT、VMAT)和系统治疗治疗量以及治疗年份(治疗年代)。使用多变量逐步泊松回归模型确定了(1)任何治疗与不治疗,以及(2)姑息治疗与非姑息治疗的相对风险(RR)。我们对患者、疾病和治疗因素进行了调整。结果我们在2010年至2018年期间发现了7093名III期NSCLC患者。在调整后的分析中,接受治疗与不接受治疗没有相关的医疗系统因素。与姑息治疗意向相关的主要卫生系统因素是居住地区(RR:地区范围从 0.88 到 1.67,p <0.001)。根据年代(2010-2012 年 vs. 2013-2015 年 vs. 2016-2018 年)进行分层,接受根治性治疗以及使用先进放疗技术和免疫疗法的人数随时间推移有所增加,但治疗意向的地区差异相似。即使放疗和全身治疗技术不断进步,这种差异依然存在。我们的研究表明,有可能通过解决无法解释的地区性治疗差异来改善治疗效果。
Health care system factors associated with receipt of treatment and treatment intent in stage III non-small cell lung cancer: A population-based study in Ontario
Purpose
Stage III non-small cell lung cancer (NSCLC) is a heterogeneous disease, with a spectrum of anatomic extent, health status, and treatment approaches. Receipt of treatment and its intent should be independent of health system factors where care quality is optimal. We investigated the degree that modifiable health system factors are associated with receipt of treatment and treatment intent in stage III NSCLC in a large, universal health system.
Methods
This was a population-based, retrospective cohort study with health administrative data from Ontario, Canada, 2010–2018 for those aged ≥ 20 years, with AJCC 7 or 8 stage III NSCLC. We explored health system factors associated with NSCLC treatment: region of residence, diagnostic interval, travel distance, advanced radiation (e.g. IMRT, VMAT) and systemic therapy treatment volumes, and year of treatment (treatment era). The relative risk (RR) of (1) any treatment versus no treatment, and (2) palliative versus non-palliative treatment was determined, using multivariable stepwise Poisson regression models. We adjusted for patient, disease, and treatment factors.
Results
We identified 7,093 people with stage III NSCLC between 2010 and 2018. There were no health system factors associated with receipt of treatment versus no treatment in adjusted analysis. The major health system factor associated with palliative intent was region of residence (RR: Region ranges from 0.88 to 1.67, p < 0.001). Stratifying by era (2010–2012 vs. 2013–2015 vs. 2016–2018), there was an increase in receipt of curative treatment and use of advanced radiotherapy techniques and immunotherapy over time, but regional variation of treatment intent was similar.
Conclusions
Region of residence emerged as the major health system factor associated with treatment intent for stage III NSCLC. This variation remained, even as advances in radiotherapy and systemic therapy were adopted. Our study suggests possible opportunities to improve care outcomes by addressing unexplained regional variation in care.